GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (MEX:FGEN) » Definitions » Cyclically Adjusted Price-to-FCF

FibroGen (MEX:FGEN) Cyclically Adjusted Price-to-FCF : (As of Jun. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is FibroGen Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


FibroGen Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for FibroGen's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Cyclically Adjusted Price-to-FCF Chart

FibroGen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

FibroGen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of FibroGen's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, FibroGen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FibroGen's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where FibroGen's Cyclically Adjusted Price-to-FCF falls into.



FibroGen Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

FibroGen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, FibroGen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-9.946/131.7762*131.7762
=-9.946

Current CPI (Mar. 2024) = 131.7762.

FibroGen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 25.003 100.560 32.765
201409 -7.874 100.428 -10.332
201412 -6.580 99.070 -8.752
201503 -10.981 99.621 -14.525
201506 22.937 100.684 30.020
201509 -10.791 100.392 -14.165
201512 -11.063 99.792 -14.609
201603 -5.026 100.470 -6.592
201606 11.938 101.688 15.470
201609 -0.570 101.861 -0.737
201612 -6.083 101.863 -7.869
201703 -8.166 102.862 -10.461
201706 -5.382 103.349 -6.862
201709 -5.216 104.136 -6.600
201712 -1.121 104.011 -1.420
201803 -7.411 105.290 -9.275
201806 -8.642 106.317 -10.711
201809 1.572 106.507 1.945
201812 -4.760 105.998 -5.918
201903 4.979 107.251 6.118
201906 -6.361 108.070 -7.756
201909 -6.647 108.329 -8.086
201912 -10.102 108.420 -12.278
202003 -15.933 108.902 -19.280
202006 38.432 108.767 46.562
202009 -0.417 109.815 -0.500
202012 -2.098 109.897 -2.516
202103 -10.144 111.754 -11.961
202106 -6.092 114.631 -7.003
202109 3.917 115.734 4.460
202112 -12.461 117.630 -13.960
202203 -9.654 121.301 -10.488
202206 -7.311 125.017 -7.706
202209 -11.315 125.227 -11.907
202212 -10.956 125.222 -11.529
202303 -19.451 127.348 -20.127
202306 -19.571 128.729 -20.034
202309 -15.110 129.860 -15.333
202312 -3.200 129.419 -3.258
202403 -9.946 131.776 -9.946

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


FibroGen  (MEX:FGEN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


FibroGen Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of FibroGen's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroGen (MEX:FGEN) Business Description

Industry
Traded in Other Exchanges
Address
409 Illinois Street, San Francisco, CA, USA, 94158
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

FibroGen (MEX:FGEN) Headlines